Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 383.33% | 266.16% | 139.43% | -36.66% | -29.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 922.92% | 1,085.49% | 911.67% | -17.81% | -25.78% |
| Operating Income | -922.92% | -1,085.49% | -911.67% | 17.81% | 25.78% |
| Income Before Tax | -800.64% | -996.05% | -2,873.66% | 19.17% | 35.18% |
| Income Tax Expenses | 6,275.00% | 2,000.00% | 650.00% | -- | -90.48% |
| Earnings from Continuing Operations | -807.01% | -996.84% | -2,877.84% | 19.31% | 35.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -807.01% | -996.84% | -2,877.84% | 19.31% | 35.61% |
| EBIT | -922.92% | -1,085.49% | -911.67% | 17.81% | 25.78% |
| EBITDA | -924.54% | -1,087.59% | -913.32% | 17.81% | 25.83% |
| EPS Basic | 84.85% | 79.41% | -2,543.31% | 30.38% | 47.19% |
| Normalized Basic EPS | 80.51% | 57.11% | -925.34% | 30.26% | 34.95% |
| EPS Diluted | 84.85% | 79.41% | -2,543.31% | 30.38% | 47.19% |
| Normalized Diluted EPS | 80.51% | 57.11% | -925.34% | 30.26% | 34.95% |
| Average Basic Shares Outstanding | 4,520.98% | 2,455.43% | 12.66% | 15.90% | 21.94% |
| Average Diluted Shares Outstanding | 4,520.98% | 2,455.43% | 12.66% | 15.90% | 21.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |